Plasminogen activators: a comparison.
Thrombolytic drugs play a crucial role in the management of patients with acute myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, acute thrombosis of retinal vessel, extensive coronary emboli, and peripheral vascular thromboembolism. Recognition of the importance of fibrinolytic system in thrombus resolution has resulted in the development of different fibrinolytic agents. Now a days several newer plasminogen activators with different pharmacokinetic and pharmacodynamic properties have been developed to treat thrombotic disease, which are fibrin specific with prolonged half-life and can be administered as a single bolus.
Baruah
Dev B
DB
Department of Quality Assurance Techniques, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune-411038, India.
Dash
Rajendra N
RN
Chaudhari
M R
MR
Kadam
S S
SS
D016255:Anistreplase / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D008666:Metalloendopeptidases / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D013300:Streptokinase / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D016255:Anistreplase; D013300:Streptokinase; D010960:Plasminogen Activators; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus